Reuters logo
BRIEF-FDA grants orphan status to Reata pharmaceuticals' bardoxolone methyl
July 10, 2017 / 11:21 AM / 2 months ago

BRIEF-FDA grants orphan status to Reata pharmaceuticals' bardoxolone methyl

July 10 (Reuters) - Reata Pharmaceuticals Inc

* ‍U.S. FDA has granted orphan designation to bardoxolone methyl for treatment of alport syndrome​

* ‍Reata expects data from phase 2 portion of trial to be available by year-end 2017​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below